{"podcast":{"title":"Blood Cancer Talks","slug":"blood-cancer-talks-5570002","podcast_index_feed_id":5570002,"rss_url":"https://feeds.transistor.fm/bloodcancertalks","website_url":null,"image_url":"https://img.transistorcdn.com/W_5G4oA5kAcf9vixuJQw-sMFE98Hvnnp4pex_BzuYvE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.jpg","author":"Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff","episode_count":75,"summary":"This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk","last_synced_at":"2026-09-03T22:19:58.611204+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002"},"episode":{"title":"Episode 67. Management of CMV in Hematologic Malignancies","slug":"episode-67-management-of-cmv-in-hematologic-malignancies","published_at":"2025-11-23T14:00:00+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-67-management-of-cmv-in-hematologic-malignancies","show_page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002","url":"https://share.transistor.fm/s/47e11e88","audio_url":"https://media.transistor.fm/47e11e88/58ecc971.mp3","summary":"Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCallum Cancer Centre and the National Centre for Infections in Cancer, for an in-depth discussion on cytomegalovirus (CMV) management in immunocompromised hematology patients. Key Topics Covered Fundamentals of CMV Management Distinguishing CMV reactivation from CMV disease Treatment thresholds and target viral loads Prophylaxis strategies in non-allograft settings Valaciclovir dosing in general hematology populations High-risk patient populations First-Line Therapies Valganciclovir: advantages, disadvantages, and myelosuppression Foscarnet: indications and monitoring strategies Treatment-resistant CMV Allogeneic Transplant Patients High-risk populations and timing of reactivation Monitoring protocols post-transplant Randomized Controlled Trials AURORA Trial: Maribavir vs. Valganciclovir Design: RCT comparing maribavir to valganciclovir for pre-emptive CMV therapy post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/38036487/] NEJM Letermovir Prophylaxis Trial Design: Double-blind, placebo-controlled RCT of letermovir prophylaxis post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/29211658/] Emerging Patient Populations CMV in lymphoma and myeloma patients receiving CAR T-cell therapy and T-cell engaging bispecific antibodies Monitoring and prophylaxis strategies for novel immunotherapies Impact of CMV on post-CAR T mortality-https://pubmed.ncbi.nlm.nih.gov/40203190/","meta_description":"Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCall…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2401,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-67-management-of-cmv-in-hematologic-malignancies/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-67-management-of-cmv-in-hematologic-malignancies.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}